metronidazole + penicillin + rifampin + ceftriaxone + vancomycin

This is a combination of five antibiotics—metronidazole, penicillin, rifampin, ceftriaxone, and vancomycin—each with distinct mechanisms of action. Such a regimen would be used in rare or highly resistant polymicrobial infections where broad-spectrum coverage is required.

• Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa by disrupting DNA synthesis.
• Penicillin (referring to the class) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
• Rifampin inhibits bacterial DNA-dependent RNA polymerase, blocking RNA synthesis.
• Ceftriaxone is a third-generation cephalosporin that also inhibits cell wall synthesis but has broader Gram-negative activity than penicillins.
• Vancomycin inhibits cell wall biosynthesis in Gram-positive bacteria by binding to D-Ala-D-Ala termini of peptidoglycan precursors.

This combination would provide extensive coverage against aerobic and anaerobic Gram-positive and Gram-negative organisms, including resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus), some Enterobacteriaceae, Pseudomonas species (with limitations), Clostridioides difficile (metronidazole), and others. It may be considered for severe mixed infections such as complicated intra-abdominal sepsis or prosthetic device infections when multidrug resistance or biofilm involvement is suspected.